Pharmaceutical Grade QSC Tirzepatide Powder - Custom Synthesis Available

QSC Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.

The QSC Tirzepatide formulation exhibits preferential binding affinity for GIP receptors while maintaining significant activity at GLP-1 receptors. This unique pharmacological profile has shown promising results in metabolic research applications. The compound mimics natural GIP activity at its receptor while providing enhanced metabolic effects.

Our QSC Tirzepatide is produced under strict quality control measures to ensure batch-to-batch consistency and high purity standards. The white powder form allows for flexible formulation in various research applications.

This product is intended for laboratory research use only. Not for human consumption. Proper handling procedures should be followed when working with this compound.